top of page
enter here
NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression
About the study
NCT Trial Number
NCT03396601
The drug being studied
Ketamine
Sponsored by
NeuroRx, Inc.|Target Health Inc.
Trial Start Date
Jun-19
About the participants
Age seeking
18 Years to 65 Years
gender
All
Primary condition of volunteers accepted
Suicidal Ideation
Accepts healthy volunteers?
No
This study will explore treatment response of a ketamine infusion, NRX-100, in achieving rapid reduction in symptoms of depression and suicidal ideation in patients with Severe Bipolar Depression and Acute Suicidal Ideation or Behavior within 24 hours of administration.
Locations
United States, Florida
Research Centers of America Recruiting
Hollywood, Florida, United States, 33024
Contact: Peter Ventre, MD
954-990-7649
United States, Texas
JP Smith Hospital
Fort Worth, Texas, United States, 76104
Contact: Alan Podawiltz, DO, MS, FAPA
817-702-3100
APodawil@JPSHealth.org
Contact: Cindy Claassen, PhD
817-702-5647
CClasse@JPSHealth.org
bottom of page